Table 1.
Demographic variable | Value | Note |
---|---|---|
Gender: n (%) | ||
Male | 30 (63.8) | |
Female | 17 (36.2) | |
Age: n (%) | Mean ± SD | |
< 30 years | 3 (6.4) | 34.15 ± 4.03 |
30-39 years | 41 (87.2) | |
40-49 years | 3 (6.4) | |
Duration of first-line ART use (months) | Min-Max (months) | |
Mean ± SD | 9.07 – 111.30 | |
Male | 54.48 ± 27.99 | 7.73 – 81.07 |
Female | 36.80 ± 19.23 | 7.73 – 111.30 |
Total | 46.81± 26.09 | p-value = 0.046 |
Initial first-line regimen | ||
d4T/3TC/NVP | 31 (66.0) | |
ZDV/3TC/NVP | 16 (34.0) | |
Risk factor | ||
Injecting drug user | 18 (38.3) | |
Sexual exposure | 18 (38.3) | |
Injecting drug user and Sexual exposure | 11 (23.4) | |
CD4 cell count | ||
< 50 | 16 (34.0) | |
50–99 | 16 (34.0) | |
100–199 | 7 (14.9) | |
200–349 | 8 (17.1) | |
≥ 350 | 0 (0) |
Abbreviation: ART, antiretroviral therapy.